Journal of Medicinal Chemistry p. 6142 - 6152 (2009)
Update date:2022-08-03
Topics: Investigation Experimental Type 2 diabetes Glucokinase activators
Bebernitz, Gregory R.
Beaulieu, Valerie
Dale, Bethany A.
Deacon, Richard
Duttaroy, Alokesh
Gao, Jiaping
Grondine, Melissa S.
Gupta, Ramesh C.
Kakmak, Mesut
Kavana, Michael
Kirman, Louise C.
Liang, Jinsheng
Maniara, Wieslawa M.
Munshi, Siralee
Nadkarni, Sunil S.
Schuster, Herbert F.
Stams, Travis
St. Denny, Irene
Taslimi, Paul M.
Vash, Brian
Caplan, Shari L.
Type 2 diabetes is a polygenic disease which afflicts nearly 200 million people worldwide and is expected to increase to near epidemic levels over the next 10-15 years. Glucokinase (GK) activators are currently under investigation by a number of pharmaceu
View MoreContact:+86 18616952870
Address:Area
Heliosense Biotechnologies, Inc.
Contact:+86-592-5667290
Address:Xiamen Torch Hi-tech Zone Venture Weiye Building S506
Shanxi Tongji Pharmaceuticals Co., Ltd.
Contact:+86-359-3024784
Address:Xikuang South Road, Ruicheng County , Shanxi
Lyrin Industrial Corporation Limited
Contact:86-731-82571800
Address:Rm 2408,Asia Economy International Building,Shaoshan Road South,Yuhua District,Changsha,Hunan,China
Suzhou Ryan Pharmachem Technology Co.,Ltd
Contact:+86-0512-68780025
Address:B-301,No.2 Taishan Road,Suzhou New District,Jiangsu,P.R. China
Doi:10.1016/0040-4020(82)80060-4
(1982)Doi:10.1055/s-1983-30357
(1983)Doi:10.1039/b508199h
(2005)Doi:10.1016/S0040-4039(00)81907-3
(1983)Doi:10.1021/om0504598
(2005)Doi:10.1021/jm00342a042
(1963)